CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking therapeutics and new materials, announced today the official launch of its biologics discovery division as a distinct brand, now known as Ailux Biologics ('Ailux')..

马萨诸塞州剑桥，2024年1月30日/PRNewswire/--XtalPi Inc.（XtalPi），一家全球领先的创新研发平台公司，利用人工智能（AI）、基于量子物理的计算和机器人自动化的力量，推动开创性治疗和新材料的发现和发展，今天宣布正式启动其生物制剂发现部门，作为一个独特的品牌，现在被称为爱力克斯生物制剂（“爱力克斯”）。。

Continue Reading

继续阅读

The name 'Ailux' reflects the team's mission to illuminate biologics discovery through AI. Lux is Latin for light and is also a standard unit of measurement for illumination. The announcement includes a new website, ailux.xtalpi.com, an affiliated LinkedIn page, and an official YouTube channel.

“Ailux”这个名字反映了该团队通过人工智能照亮生物制剂发现的使命。Lux是拉丁语中的光，也是照明的标准测量单位。该公告包括一个新网站ailux.xtalpi.com、一个LinkedIn附属页面和一个YouTube官方频道。

XtalPi has already established a strong track record by forging partnerships with numerous pharma and biotech companies globally. This strategic branding move marks a significant milestone in the division's rapid growth and underscores XtalPi's commitment to delivering innovative solutions to its partners in the drug discovery sectors..

XtalPi通过与全球众多制药和生物技术公司建立合作关系，已经建立了良好的业绩记录。这一战略性品牌举措标志着该部门快速增长的一个重要里程碑，并强调了XtalPi致力于为药物发现领域的合作伙伴提供创新解决方案。。

Dr. Jian Ma, CEO of XtalPi, commented on the launch of Ailux, 'In recent years, XtalPi's discovery solutions have produced strong evidence regarding the power of AI in biologics R&D. XtalPi's biologics team have an advanced approach to machine learning in drug discovery, particularly in finding the most relevant and transformational applications of it.

XtalPi首席执行官马健博士对爱乐士的推出发表了评论，“近年来，XtalPi的发现解决方案为人工智能在生物制剂研发中的作用提供了有力证据。XtalPi的生物制剂团队在药物发现中拥有先进的机器学习方法，特别是在寻找最相关和最具变革性的应用方面。

There's great potential in how our technologies can advance the entire biologics discovery ecosystem.'Under the Ailux brand, the team will continue to focus on revolutionizing biologics drug discovery through a fusion of proprietary AI algorithms and wet lab methods that target the industry's most challenging bottlenecks, in line with XtalPi's continued mission of accelerating the drug discovery process.'Our platform is comprised of a suite of specialized solutions.

我们的技术如何推进整个生物制剂发现生态系统具有巨大潜力。”在Ailux品牌下，该团队将继续专注于通过融合专有AI算法和针对行业最具挑战性瓶颈的湿实验室方法来彻底改变生物制剂药物的发现，这符合XtalPi加速药物发现过程的持续使命。”我们的平台由一套专门的解决方案组成。

Over years of rigorous testing, we've identified the precise areas where AI provides the maximum impact in biologics discovery. Our platform is fully validated so that our partners can benefit immediately from the best-in-class AI solutions we've built,' stated Alex Li, VP of Antibody Discovery at XtalPi and head of the Ailux team.XtalPi invites partners to bring them challenging targets.

经过多年的严格测试，我们已经确定了人工智能在生物制剂发现中发挥最大影响的确切领域。XtalPi抗体发现副总裁兼Ailux团队负责人Alex Li表示，我们的平台经过充分验证，因此我们的合作伙伴可以立即从我们构建的一流AI解决方案中受益。XtalPi邀请合作伙伴为他们带来具有挑战性的目标。

The team leverages AI to interrogate a wider pool of potential hits, engineer lead antibodies faster, and assess developability at ultra-high throughput. Meanwhile, teams of computational experts and seasoned wet-lab scientists are constantly developing and validating new AI-powered algorithms to help partners stay ahead of the curve in biologics discovery.About XtalPiXtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics.

该团队利用人工智能来询问更广泛的潜在命中率，更快地设计铅抗体，并评估超高通量的可开发性。与此同时，由计算专家和经验丰富的湿实验室科学家组成的团队正在不断开发和验证新的人工智能算法，以帮助合作伙伴在生物制剂发现方面保持领先地位。关于XtalPiXtalPi是一家由人工智能（AI）和机器人技术支持的创新技术公司。

Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the li.

XtalPi成立于2015年，位于麻省理工学院校园，致力于推动li的智能化和数字化转型。